A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity

Prior treatment

• Severe infections, significant trauma, or major surgery within 30 days prior to screening, as judged by the investigator.
• Use of medications or treatments that may cause significant weight gain or loss within 90 days prior to screening.

Other illness

• Uncontrolled severe hypertension at the screening period.
• Presence of endocrine diseases that may significantly affect the body weight.
• History of acute or chronic pancreatitis.
• History of significant gastrointestinal diseases.
• Any condition deemed by the investigator to be unsuitable for participation in this clinical trial.

Lab values

• At the screening period, relevant laboratory test results are abnormal.

Other

• Electrocardiogram (ECG) results at the screening period show clinically significant abnormalities.
• Known or suspected abuse of alcohol or narcotics.

• On the day of signing the informed consent form, the age should be between 18 and 75 years old.
• At the screening period, the Body Mass Index (BMI) should meet the criteria of ≥ 28.0 kg/m², or ≥ 24.0 kg/m² with at least one weight-related comorbidity, such as hyperglycemia, hypertension, dyslipidemia, obstructive sleep apnea, or non-alcoholic fatty liver disease.
• The participant should have controlled their diet and exercise for 3 months or more prior to screening and randomization, and the weight change in the past 3 months should not exceed 5%.
• Before the trial, the participants must voluntarily sign the informed consent form, fully understand the trial content, procedures and potential adverse reactions, and have the ability and willingness to comply with the protocol requirements to complete this study.